Pfizer, OPKO Get FDA Nod for Pediatric Growth Hormone Deficiency Drug

Overcoming an FDA rejection in January 2022, Pfizer and OPKO’s Ngenla will provide a long-acting, reduced-frequency treatment option for children with growth hormone deficiency.